Dr. Lal PathLabs Limited

Informe acción NSEI:LALPATHLAB

Capitalización de mercado: ₹262.5b

Dr. Lal PathLabs Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Dr. Lal PathLabs de 11.8% y 10.5% por año respectivamente. Se prevé que el BPA crezca en un 11.5% al año. Se espera que la rentabilidad financiera sea de 22.5% en 3 años.

Información clave

11.8%

Tasa de crecimiento de los beneficios

11.50%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare27.4%
Tasa de crecimiento de los ingresos10.5%
Rentabilidad financiera futura22.47%
Cobertura de analistas

Good

Última actualización04 Nov 2025

Actualizaciones recientes sobre el crecimiento futuro

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05
Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Feb 03
Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Recent updates

Dr. Lal PathLabs (NSE:LALPATHLAB) Is Increasing Its Dividend To ₹7.00

Nov 07
Dr. Lal PathLabs (NSE:LALPATHLAB) Is Increasing Its Dividend To ₹7.00

Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Sep 29
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching

Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Sep 01
Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Aug 18
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 05
Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Jul 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon

Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Jun 24
Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Jun 03
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Apr 28
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Apr 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Mar 04
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
User avatar

Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India

Government health spending and rising NCD prevalence are likely to boost Dr. Lal PathLabs' patient volumes and revenues.

Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Feb 03
Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report

Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

Jan 16
Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jan 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Previsiones de crecimiento de beneficios e ingresos

NSEI:LALPATHLAB - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
3/31/202834,2916,9587,438N/A20
3/31/202730,8636,0286,438N/A23
3/31/202627,4325,1875,047N/A22
6/30/202525,2935,131N/AN/AN/A
3/31/202524,6144,8715,1505,689N/A
12/31/202424,0424,168N/AN/AN/A
9/30/202423,4644,0144,9125,365N/A
6/30/202422,8753,815N/AN/AN/A
3/31/202422,2663,5774,7795,353N/A
12/31/202321,7223,298N/AN/AN/A
9/30/202321,2273,0134,7675,198N/A
6/30/202320,5522,638N/AN/AN/A
3/31/202320,1692,3884,1154,560N/A
12/31/202220,1142,435N/AN/AN/A
9/30/202220,1892,480-8243,884N/A
6/30/202219,8352,713N/AN/AN/A
3/31/202220,8743,448-2944,467N/A
12/31/202120,3293,669N/AN/AN/A
9/30/202119,8844,0414,6095,327N/A
6/30/202119,2193,944N/AN/AN/A
3/31/202115,8132,9163,3863,982N/A
12/31/202014,5202,407N/AN/AN/A
9/30/202013,2752,0032,2592,821N/A
6/30/202012,6121,955N/AN/AN/A
3/31/202013,3042,2592,0432,839N/A
12/31/201913,2982,405N/AN/AN/A
9/30/201912,9442,3222,1992,619N/A
6/30/201912,4632,086N/AN/AN/A
3/31/201912,0341,992N/A2,185N/A
12/31/201811,6911,923N/AN/AN/A
9/30/201811,3931,825N/AN/AN/A
6/30/201810,9991,761N/AN/AN/A
3/31/201810,5691,707N/A1,971N/A
12/31/201710,1001,617N/AN/AN/A
9/30/20179,5481,565N/AN/AN/A
6/30/20179,3891,586N/AN/AN/A
3/31/20179,1241,546N/A1,713N/A
12/31/20168,9021,576N/AN/AN/A
9/30/20168,7131,876N/AN/AN/A
6/30/20168,2491,413N/AN/AN/A
3/31/20167,9131,322N/A1,585N/A
12/31/20157,6541,201N/AN/AN/A
3/31/20156,596908N/A1,218N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.8% al año) de LALPATHLAB es superior a la tasa de ahorro (6.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (11.8% al año) de LALPATHLAB crezcan menos que el mercado Indian (16.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de LALPATHLAB crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (10.5% al año) de LALPATHLAB crezcan más despacio que el mercado de Indian (10.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.5% al año) de LALPATHLAB crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de LALPATHLAB sea alta dentro de 3 años (22.5%)

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/11/22 01:23
Precio de las acciones al final del día2025/11/21 00:00
Beneficios2025/06/30
Ingresos anuales2025/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Dr. Lal PathLabs Limited está cubierta por 51 analistas. 23 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Prashant NairAmbit Capital
Ashwin MehtaAmbit Capital
Nitin BhasinAmbit Capital